Rekhtman et al. suggested that both NSCLC-like and SCLC-like LCNEC patients may be sensitive to PD-1/PD-L1 immune checkpoint inhibitors [16]. This evidence concerns the gene CD274 and large cell neuroendocrine carcinoma.